Drug Trial Radar · NCT00375258
Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage
Last checked: Nov 19, 2026Latest source record: Jun 30, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20,211
Actual
Start
May 2005
Primary completion
Feb 2010
Study completion Mar 2010
Sponsor
- Lead sponsor
- London School of Hygiene and Tropical MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 12, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CRASH 2 is a large pragmatic randomised placebo controlled trial of the effects of the early administration of the antifibrinolytic agent tranexamic acid on death, vascular events and transfusion requirements. Adults with trauma who are within 8 hours of injury and have either significant haemorrhage, or who are considered to be at risk of significant haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Numbered drug or placebo packs will be available in each participating emergency department. Randomisation will involve calling a 24-hour freecall randomisation service. The call should last only a minute or two and at the end of it the randomisation service will specify which numbered treatment pack to use. For hospitals where telephone randomisation is not feasible, randomisation will be by taking the next consecutively numbered treatment pack. No extra tests are required but a short form must be completed one month later or on discharge or on death (whichever occurs first).
Conditions
- Hemorrhage
Interventions
Tranexamic acidDrug
Loading dose of 1 gram then 1 gram by infusion over 8 hours
Sodium Chloride 0.9%Drug
Visual matched placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Death in hospital within four weeks of injury (causes of death will be described to assess whether deaths were due to haemorrhage or vascular occlusion).Time frame: Death, discharge or four weeks post randomisation whichever occurs first.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Over 50 countries Worldwide
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.